Intellia Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	66.09	67.67	57.88	36.28	52.12	33.05
Revenue Growth (YoY)	45.04%	16.92%	59.55%	-30.40%	57.69%	-43.01%
Gross Profit	66.09	67.67	57.88	36.28	52.12	33.05
Selling, General & Admin	125.64	119.8	125.83	116.5	90.31	71.1
Research & Development	361.17	388.86	466.31	435.07	419.98	229.81
Total Operating Expenses	486.81	508.66	592.14	551.57	510.29	300.9
Operating Income	-420.72	-440.99	-534.26	-515.29	-458.16	-267.85
Interest Income	25.8	29.2	47.81	49.83	8.54	1.28
Other Non-Operating Income (Expense)	0.32	-0.9	-32.57	-15.73	-24.56	-1.33
Total Non-Operating Income (Expense)	26.12	28.3	15.24	34.1	-16.02	-0.04
Pretax Income	-394.6	-412.69	-519.02	-481.19	-474.19	-267.89
Net Income	-394.6	-412.69	-519.02	-481.19	-474.19	-267.89
Net Income to Common	-394.6	-412.69	-519.02	-481.19	-474.19	-267.89
Shares Outstanding (Basic)	112	108	99	89	77	71
Shares Outstanding (Diluted)	112	108	99	89	77	71
Shares Change (YoY)	11.16%	9.64%	11.35%	15.33%	8.57%	26.63%
EPS (Basic)	-3.54	-3.81	-5.25	-5.42	-6.16	-3.78
EPS (Diluted)	-3.54	-3.81	-5.25	-5.42	-6.16	-3.78
Free Cash Flow	-363.63	-395.87	-354.66	-408.07	-346.85	-237.79
Free Cash Flow Per Share	-3.24	-3.65	-3.59	-4.60	-4.51	-3.35
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-636.56%	-651.67%	-923.10%	-1420.51%	-879.04%	-810.37%
Profit Margin	-597.04%	-609.85%	-896.77%	-1326.51%	-909.78%	-810.49%
FCF Margin	-550.18%	-584.99%	-612.78%	-1124.94%	-665.46%	-719.41%
EBITDA	-411.24	-431.22	-523.98	-506.32	-450.59	-260.96
EBITDA Margin	-622.23%	-637.24%	-905.33%	-1395.77%	-864.51%	-789.52%
EBIT	-420.72	-440.99	-534.26	-515.29	-458.16	-267.85
EBIT Margin	-636.56%	-651.67%	-923.10%	-1420.51%	-879.04%	-810.37%

SEC Filings: 10-K · 10-Q